|Articles|June 26, 2011

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

Can AI rescue physicians from Medicare's documentation arms race?

Your patients are sourcing compounded GLP-1s online. Here's what to do about it

How doctors can negotiate a better employment contract

What your practice is actually worth, with Andy Colbert of Ziegler

Six charged in $20M health care fraud; hospitals urged to cut ultra-processed food; less scrolling, better sleep — Morning Medical Update